07-13-06

CASE 20682D



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 731065513 US Express Mail Label Number July 12, 2006

Number Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ALESSI ET AL.

APPLICATION NO: 10/823,433

FILED: APRIL 12, 2004

FOR: FOR RAC-PK AS A THERAPEUTIC AGENT OR IN DIAGNOSTICS,

SCREENING METHOD FOR AGENTS AND PROCESS FOR

ACTIVATING RAC-PK

MS: Amendment Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to the restriction requirement of March 14, 2006, Applicants hereby elect Group 1, claims 1-8, 19, 31, 32, and 34, drawn to modulators of RAC-PK activity, a RAC-PK polypeptide, pharmaceutical compositions comprising RAC-PK, its analogs, isoforms, inhibitors, or activators to regulate glycogen metabolism and/or protein synthesis, classified in class 514, subclass 2. Applicants hereby elect species (a) pharmaceutical compositions comprising RAC-PK, its analogs or isoforms and therapeutic methods of using the same. Applicants respectfully request that if the elected species is found allowable, the Examiner shall move to the next species as required by Election of species practice.

Applicant submit a petition for Three Months Extension of Time herewith, and believe that no additional fees are due with this filing. However, if it is deemed that additional fees are required, the Commissioner is authorized to charge Deposit Account No. 19-0134 in the name of Novartis for any fees due.

JAV J

An early and favorable action on the merits is respectfully requested.

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (617) 871-4125

Date: July 12, 2006

Respectfully submitted,

Mark Milstead

Attorney for Applicant

Reg. No. 45,825